1
|
Miguel-Carrera J, García-Porrua C, de Toro Santos FJ, Picallo-Sánchez JA. [Prevalence of osteoporosis, estimation of probability of fracture and bone metabolism study in patients with newly diagnosed prostate cancer in the health area of Lugo]. Aten Primaria 2018. [PMID: 28629885 PMCID: PMC6837155 DOI: 10.1016/j.aprim.2017.03.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
OBJECTIVE To study the prevalence of osteoporosis and fracture probability in patients diagnosed with prostate cancer. DESIGN Observational descriptive transversal study. SITE: Study performed from Primary Care of Lugo in collaboration with Rheumatology and Urology Services of our referral hospital. PARTICIPANTS Patients diagnosed with prostate cancer without bone metastatic disease from January to December 2012. MAIN MEASUREMENTS Epidemiologic, clinical, laboratory and densitometric variables involved in osteoporosis were collected. The likelihood of fracture was estimated by FRAX® Tool. RESULTS Eighty-three patients met the inclusion criteria. None was excluded. The average age was 67 years. The Body Mass Index was 28.28. Twenty-five patients (30.1%) had previous osteoporotic fractures. Other prevalent risk factors were alcohol (26.5%) and smoking (22.9%). Eighty-two subjects had vitamin D below normal level (98.80%). Femoral Neck densitometry showed that 8.9% had osteoporosis and 54% osteopenia. The average fracture risk in this population, estimated by FRAX®, was 2.63% for hip fracture and 5.28% for major fracture. Cut level for FRAX® major fracture value without DXA >5% and ≥7.5% proposed by Azagra et al. showed 24 patients (28.92%) and 8 patients (9.64%) respectively. CONCLUSIONS The prevalence of osteoporosis in this population was very high. The more frequent risk factors associated with osteoporosis were: previous osteoporotic fracture, alcohol consumption, smoking and family history of previous fracture. The probability of fracture using femoral neck FRAX® tool was low. Vitamin D deficiency was very common (98.8%).
Collapse
Affiliation(s)
- Jonatan Miguel-Carrera
- Punto de Atención Continuada Fingoi (Lugo), Estructura Organizativa de Gestión Integrada (EOXI) Lugo, Cervo y Monforte, Servicio Galego de Saúde (SERGAS), Lugo, España.
| | - Carlos García-Porrua
- Sección de Reumatología, Hospital Universitario Lucus Augusti (HULA), Servicio Galego de Saúde (SERGAS), Lugo, España
| | - Francisco Javier de Toro Santos
- Servicio de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complejo Hospitalario Universitario de A Coruña (CHUAC), Servicio Galego de Saúde (SERGAS), Universidade da Coruña (UDC), A Coruña, España
| | - Jose Antonio Picallo-Sánchez
- Servicio de Urología, Complejo Hospitalario Universitario de A Coruña, Servicio Galego de Saúde (SERGAS), A Coruña, España
| |
Collapse
|
2
|
Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV. A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 2016; 11:25. [PMID: 27465509 PMCID: PMC4978487 DOI: 10.1007/s11657-016-0278-z] [Citation(s) in RCA: 285] [Impact Index Per Article: 31.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 06/16/2016] [Indexed: 02/03/2023]
Abstract
UNLABELLED This systematic review identified assessment guidelines for osteoporosis that incorporate FRAX. The rationale for intervention thresholds is given in a minority of papers. Intervention thresholds (fixed or age-dependent) need to be country-specific. INTRODUCTION In most assessment guidelines, treatment for osteoporosis is recommended in individuals with prior fragility fractures, especially fractures at spine and hip. However, for those without prior fractures, the intervention thresholds can be derived using different methods. The aim of this report was to undertake a systematic review of the available information on the use of FRAX® in assessment guidelines, in particular the setting of thresholds and their validation. METHODS We identified 120 guidelines or academic papers that incorporated FRAX of which 38 provided no clear statement on how the fracture probabilities derived are to be used in decision-making in clinical practice. The remainder recommended a fixed intervention threshold (n = 58), most commonly as a component of more complex guidance (e.g. bone mineral density (BMD) thresholds) or an age-dependent threshold (n = 22). Two guidelines have adopted both age-dependent and fixed thresholds. RESULTS Fixed probability thresholds have ranged from 4 to 20 % for a major fracture and 1.3-5 % for hip fracture. More than one half (39) of the 58 publications identified utilised a threshold probability of 20 % for a major osteoporotic fracture, many of which also mention a hip fracture probability of 3 % as an alternative intervention threshold. In nearly all instances, no rationale is provided other than that this was the threshold used by the National Osteoporosis Foundation of the USA. Where undertaken, fixed probability thresholds have been determined from tests of discrimination (Hong Kong), health economic assessment (USA, Switzerland), to match the prevalence of osteoporosis (China) or to align with pre-existing guidelines or reimbursement criteria (Japan, Poland). Age-dependent intervention thresholds, first developed by the National Osteoporosis Guideline Group (NOGG), are based on the rationale that if a woman with a prior fragility fracture is eligible for treatment, then, at any given age, a man or woman with the same fracture probability but in the absence of a previous fracture (i.e. at the 'fracture threshold') should also be eligible. Under current NOGG guidelines, based on age-dependent probability thresholds, inequalities in access to therapy arise especially at older ages (≥70 years) depending on the presence or absence of a prior fracture. An alternative threshold using a hybrid model reduces this disparity. CONCLUSION The use of FRAX (fixed or age-dependent thresholds) as the gateway to assessment identifies individuals at high risk more effectively than the use of BMD. However, the setting of intervention thresholds needs to be country-specific.
Collapse
Affiliation(s)
- John A Kanis
- Centre for Metabolic Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.
- Institute of Health and Ageing, Australian Catholic University, Melbourne, Australia.
| | - Nicholas C Harvey
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
| | - Cyrus Cooper
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
| | - Helena Johansson
- Centre for Metabolic Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
| | - Anders Odén
- Centre for Metabolic Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
| | - Eugene V McCloskey
- Centre for Metabolic Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
| |
Collapse
|
3
|
Azagra R, Roca G, Martín-Sánchez JC, Casado E, Encabo G, Zwart M, Aguyé A, Díez-Pérez A. [FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population]. Med Clin (Barc) 2014; 144:1-8. [PMID: 24461732 DOI: 10.1016/j.medcli.2013.11.014] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Revised: 11/05/2013] [Accepted: 11/07/2013] [Indexed: 01/20/2023]
Abstract
BACKGROUND AND OBJECTIVE To detect FRAX(®) threshold levels that identify groups of the population that are at high/low risk of osteoporotic fracture in the Spanish female population using a cost-effective assessment. PATIENTS AND METHODS This is a cohort study. Eight hundred and sixteen women 40-90 years old selected from the FRIDEX cohort with densitometry and risk factors for fracture at baseline who received no treatment for osteoporosis during the 10 year follow-up period and were stratified into 3 groups/levels of fracture risk (low<10%, 10-20% intermediate and high>20%) according to the real fracture incidence. RESULTS The thresholds of FRAX(®) baseline for major osteoporotic fracture were: low risk<5; intermediate ≥ 5 to <7.5 and high ≥ 7.5. The incidence of fracture with these values was: low risk (3.6%; 95% CI 2.2-5.9), intermediate risk (13.7%; 95% CI 7.1-24.2) and high risk (21.4%; 95% CI12.9-33.2). The most cost-effective option was to refer to dual energy X-ray absorptiometry (DXA-scan) for FRAX(®)≥ 5 (Intermediate and high risk) to reclassify by FRAX(®) with DXA-scan at high/low risk. These thresholds select 17.5% of women for DXA-scan and 10% for treatment. With these thresholds of FRAX(®), compared with the strategy of opportunistic case finding isolated risk factors, would improve the predictive parameters and reduce 82.5% the DXA-scan, 35.4% osteoporosis prescriptions and 28.7% cost to detect the same number of women who suffer fractures. CONCLUSIONS The use of FRAX ® thresholds identified as high/low risk of osteoporotic fracture in this calibration (FRIDEX model) improve predictive parameters in Spanish women and in a more cost-effective than the traditional model based on the T-score ≤ -2.5 of DXA scan.
Collapse
Affiliation(s)
- Rafael Azagra
- Departamento de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Medicina de Familia, CAP Badía del Vallés, Institut Català de la Salut (ICS), USR MN-IDIAP Jordi Gol, Barcelona, España; Departamento de Medicina, Universitat Internacional de Catalunya, Sant Cugat del Vallés, Barcelona, España.
| | - Genís Roca
- Departamento de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Medicina de Familia, CAP Sant Llàtzer, Corporació Sanitària de Terrassa, Terrassa, Barcelona, España
| | - Juan Carlos Martín-Sánchez
- Bioestadística, Departamento de Ciencias Básicas, Universitat Internacional de Catalunya, Campus Sant Cugat, Sant Cugat del Vallés, Barcelona, España
| | - Enrique Casado
- Reumatología, Hospital de Sabadell, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, España
| | - Gloria Encabo
- Medicina Nuclear, Hospital Universitari Vall d'Hebron, Institut Català de la Salut (ICS), Barcelona, España
| | - Marta Zwart
- Departamento de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Medicina de Familia, CAP Girona-2, Institut Català de la Salut (ICS)-USR Girona, IDIAP Jordi Gol, Girona, España
| | - Amada Aguyé
- Medicina de Familia, CAP Granollers Centre, Institut Català de la Salut (ICS), Granollers, Barcelona, España
| | - Adolf Díez-Pérez
- Departamento de Medicina, Universitat Autònoma de Barcelona, Barcelona, España; Departamento de Medicina Interna, URFOA, IMIM, Parc de Salut Mar, Barcelona, España; Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF), Instituto de Salud Carlos III-FEDER, Madrid, España
| | | |
Collapse
|
5
|
Azagra R, Roca G, Encabo G, Aguyé A, Zwart M, Güell S, Puchol N, Gene E, Casado E, Sancho P, Solà S, Torán P, Iglesias M, Gisbert MC, López-Expósito F, Pujol-Salud J, Fernandez-Hermida Y, Puente A, Rosàs M, Bou V, Antón JJ, Lansdberg G, Martín-Sánchez JC, Díez-Pérez A, Prieto-Alhambra D. FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort. BMC Musculoskelet Disord 2012; 13:204. [PMID: 23088223 PMCID: PMC3518201 DOI: 10.1186/1471-2474-13-204] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2011] [Accepted: 10/09/2012] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND The WHO has recently published the FRAX® tool to determine the absolute risk of osteoporotic fracture at 10 years. This tool has not yet been validated in Spain. METHODS/DESIGN A prospective observational study was undertaken in women in the FRIDEX cohort (Barcelona) not receiving bone active drugs at baseline. Baseline measurements: known risk factors including those of FRAX® and a DXA. Follow up data on self-reported incident major fractures (hip, spine, humerus and wrist) and verified against patient records. The calculation of absolute risk of major fracture and hip fracture was by FRAX® website. This work follows the guidelines of the STROBE initiative for cohort studies. The discriminative capacity of FRAX® was analyzed by the Area Under Curve (AUC), Receiver Operating Characteristics (ROC) and the Hosmer-Lemeshow goodness-of-fit test. The predictive capacity was determined using the ratio of observed fractures/expected fractures by FRAX® (ObsFx/ExpFx). RESULTS The study subjects were 770 women from 40 to 90 years of age in the FRIDEX cohort. The mean age was 56.8 ± 8 years. The fractures were determined by structured telephone questionnaire and subsequent testing in medical records at 10 years. Sixty-five (8.4%) women presented major fractures (17 hip fractures). Women with fractures were older, had more previous fractures, more cases of rheumatoid arthritis and also more osteoporosis on the baseline DXA. The AUC ROC of FRAX® for major fracture without bone mineral density (BMD) was 0.693 (CI 95%; 0.622-0.763), with T-score of femoral neck (FN) 0.716 (CI 95%; 0.646-0.786), being 0.888 (CI 95%; 0.824-0.952) and 0.849 (CI 95%; 0.737-0.962), respectively for hip fracture. In the model with BMD alone was 0.661 (CI 95%; 0.583-0.739) and 0.779 (CI 95%; 0.631-0.929). In the model with age alone was 0.668 (CI 95%; 0.603-0.733) and 0.882 (CI 95%; 0.832-0.936). In both cases there are not significant differences against FRAX® model. The overall predictive value for major fracture by ObsFx/ExpFx ratio was 2.4 and 2.8 for hip fracture without BMD. With BMD was 2.2 and 2.3 respectively. Sensitivity of the four was always less than 50%. The Hosmer-Lemeshow test showed a good correlation only after calibration with ObsFx/ExpFx ratio. CONCLUSIONS The current version of FRAX® for Spanish women without BMD analysed by the AUC ROC demonstrate a poor discriminative capacity to predict major fractures but a good discriminative capacity for hip fractures. Its predictive capacity does not adjust well because leading to underdiagnosis for both predictions major and hip fractures. Simple models based only on age or BMD alone similarly predicted that more complex FRAX® models.
Collapse
Affiliation(s)
- Rafael Azagra
- Department of Medicine, Universitat Autònoma de Barcelona (UAB), Psg Vall d’Hebrón 119-129, 08035, Barcelona, Spain
- Badia del Vallès Health Centre, Catalan Health Institute. USR-MN-IDIAP Jordi Gol. c/ Bética s/n, 08214, Barcelona, Badia del Vallès, Spain
- Doctorate Program, Department of Medicine, Universitat Autònoma de Barcelona (UAB). Psg Vall d’Hebrón 119–129, 08035, Barcelona, Spain
| | - Genís Roca
- Doctorate Program, Department of Medicine, Universitat Autònoma de Barcelona (UAB). Psg Vall d’Hebrón 119–129, 08035, Barcelona, Spain
- Sant Llàtzer Health Centre, Sanitary Consortium of Terrassa. c/ de la Riba 62, 08221, Barcelona, Terrassa, Spain
| | - Gloria Encabo
- Nuclear Medicine Service, Vall d’Hebrón University Hospital. Psg Vall d’Hebrón 119–129, 08035, Barcelona, Spain
| | - Amada Aguyé
- Granollers Centre Health Centre, Catalan Health Institute. c/ Museu 19, 08400, Barcelona, Granollers, Spain
| | - Marta Zwart
- Doctorate Program, Department of Medicine, Universitat Autònoma de Barcelona (UAB). Psg Vall d’Hebrón 119–129, 08035, Barcelona, Spain
- Can Gibert del Plà-Girona-2 Health Centre, Catalan Health Institute. c/ Sant Sebastià 50, 17005, Girona, Spain
| | - Sílvia Güell
- Montcada i Reixach Health Centre, Catalan Health Institute. Psg de Jaume I s/n, 08110, Barcelona, Montcada i Reixac, Spain
| | - Núria Puchol
- Badia del Vallès Health Centre, Catalan Health Institute. USR-MN-IDIAP Jordi Gol. c/ Bética s/n, 08214, Barcelona, Badia del Vallès, Spain
| | - Emili Gene
- Emergency Department, Hospital de Sabadell, Sanitary Consortium of Parc Taulí, Universitat Autònoma de Barcelona. Parc Tauli s/n, 08208, Barcelona, Sabadell, Spain
- Universitat Internacional de Catalunya (UIC), c/ Josep Trueta s/n 08195 Sant Cugat del Vallès, Barcelona, Spain
| | - Enrique Casado
- Rheumatology Department, Hospital de Sabadell, Sanitary Consortium of Parc Taulí, Universitat Autònoma de Barcelona. Parc Tauli s/n, 08208, Barcelona, Sabadell, Spain
| | - Pilar Sancho
- Corbera de Llobregat Health Centre, Catalan Health Institute. c/ Buenos Aires, 9, 08757, Barcelona, Corbera de Llobregat, Spain
| | - Silvia Solà
- Emergency Department, University Hospital of Bellvitge, Catalan Health Institute. University of Barcelona. c/ de la Feixa Llarga s/n, 08907, Barcelona, L'Hospitalet de Llobregat, Spain
| | - Pere Torán
- Primary Health Research Support Unit Metropolitana Nord, Catalan Health Institute-IDIAP Jordi Gol. Rambla 227, 08223, Barcelona, Sabadell, Spain
| | - Milagros Iglesias
- Badia del Vallès Health Centre, Catalan Health Institute. USR-MN-IDIAP Jordi Gol. c/ Bética s/n, 08214, Barcelona, Badia del Vallès, Spain
| | - Maria Carmen Gisbert
- Cabrils Health Centre, Catalan Health Institute. c/ Cal Batalló 3, 08348, Cabrils, Barcelona, Spain
| | - Francesc López-Expósito
- Department of Medicine, Universitat Autònoma de Barcelona (UAB), Psg Vall d’Hebrón 119-129, 08035, Barcelona, Spain
- Bon Pastor Health Centre. Health Institute. c/ Mollerussa s/n, 08030, Barcelona, Spain
| | - Jesús Pujol-Salud
- Balaguer Health Centre, Catalan Health Institute. Universitat de Lleida. c/ Àngel Guimerà, 24 25600, Lleida, Balaguer, Spain
| | - Yolanda Fernandez-Hermida
- Doctorate Program, Department of Medicine, Universitat Autònoma de Barcelona (UAB). Psg Vall d’Hebrón 119–129, 08035, Barcelona, Spain
- Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK
| | - Ana Puente
- Taradell Health Centre, Catalan Health Institute, C. Passeig del Pujaló, 5, 08552, Barcelona, Taradell, Spain
| | - Mireia Rosàs
- Granollers Centre Health Centre, Catalan Health Institute. c/ Museu 19, 08400, Barcelona, Granollers, Spain
| | - Vicente Bou
- Sanllehy Health Centre. Catalan Health Institute. Av. Mare de Déu de Montserrat, 16–18, 08024, Barcelona, Spain
| | - Juan José Antón
- Poble Sec 3B Health Centre, CAP Manso. Catalan Health Institute. c/ Manso, 19–27, 08015, Barcelona, Spain
| | - Gustavo Lansdberg
- Universidade de José do Rosàrio Vellano. UNIFENAS, Belo Horizonte. Rua Libano - Bairro Itapoã 66, Belo Horizonte, 31710-030, Minas Gerais, Brasil
| | - Juan Carlos Martín-Sánchez
- Universitat Internacional de Catalunya (UIC), c/ Josep Trueta s/n 08195 Sant Cugat del Vallès, Barcelona, Spain
| | - Adolf Díez-Pérez
- Institut Municipal d'Investigacions Mèdiques (IMIM)-Parc de Salut Mar, URFOA, Internal Medicine, Universitat Autònoma de Barcelona. Psg Marítim 25, 08003, Barcelona, Spain
| | - Daniel Prieto-Alhambra
- Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, UK
- Institut Municipal d'Investigacions Mèdiques (IMIM)-Parc de Salut Mar, URFOA, Internal Medicine, Universitat Autònoma de Barcelona. Psg Marítim 25, 08003, Barcelona, Spain
| |
Collapse
|